This report provides information on the therapeutic development for HIV-Associated Lipodystrophy Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for HIV-Associated Lipodystrophy Syndrome. 'HIV-Associated Lipodystrophy Syndrome - Pipeline Review, H1 2012' is built using data and information sourced from Global Industries Direct’s proprietary databases, Firms /University websites, SEC filings, investor presentations and featured press releases from firm /university sites and market -specific third party sources, put together by Global Industries Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope of the Research

- A snapshot of the global therapeutic scenario for HIV-Associated Lipodystrophy Syndrome.
- A review of the HIV-Associated Lipodystrophy Syndrome products under development by industry players and universities/research institutes based on information derived from industry player and market -specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the HIV-Associated Lipodystrophy Syndrome pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Why Should You Get This Report?

- Identify and understand important and diverse types of therapeutics under development for HIV-Associated Lipodystrophy Syndrome.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and take over s effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding HIV-Associated Lipodystrophy Syndrome pipeline depth and focus of HIV-Associated Lipodystrophy Syndrome therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and grow business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global March kets Direct Report Coverage 6
HIV-Associated Lipodystrophy Syndrome Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for HIV-Associated Lipodystrophy Syndrome 8
HIV-Associated Lipodystrophy Syndrome Therapeutics under Development by Firms 10
HIV-Associated Lipodystrophy Syndrome Therapeutics under Investigation by Universities/Institutes 11
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
HIV-Associated Lipodystrophy Syndrome Therapeutics - Products under Development by Firms 16
HIV-Associated Lipodystrophy Syndrome Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in HIV-Associated Lipodystrophy Syndrome Therapeutics Development 18
Ark Therapeutics Group plc 18
Zydus Cadila Healthcare Limited 19
Theratechnologies Inc. 20
HIV-Associated Lipodystrophy Syndrome - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
Tesamorelin - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
ZYH1 - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Pioglitazone + Leptin - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Recombinant Human Growth Hormone - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Avandia - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Recombinant Human Growth Hormone + Rosiglitazone - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Leptin - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
EG005 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
Recombinant IGF-I - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
Eutrophill - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Eutrophill - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
HIV-Associated Lipodystrophy Syndrome Therapeutics - Drug Profile Updates 40
HIV-Associated Lipodystrophy Syndrome Therapeutics - Dormant Products 42
HIV-Associated Lipodystrophy Syndrome - Product Development Milestones 43
Featured News and Press Releases 43
October 19, 2011: Theratechnologies Announces Application For Registration Of Tesamorelin In Mexico 43
July 05, 2011: Theratechnologies Announces Filing Of Application For Registration Of Tesamorelin In Israel By Sanofi 43
June 06, 2011: Theratechnologies Announces Filing Of European March keting Authorization Application For Tesamorelin 44
June 24, 2010: Theratechnologies Announces Publication Of Combined Tesamorelin Phase III Results In JCEM 44
May 27, 2010: Theratechnologies Announces Positive Vote By FDA Advisory Committee For Tesamorelin 45
March 22, 2010: FDA Confirms Date For Advisory Committee Review Of Theratechnologies' Tesamorelin New Drug Application 45
March 01, 2010: Theratechnologies Announces Publication Of Second Phase III Results Of Tesamorelin In JAIDS 46
February 25, 2010: Theratechnologies Announces Tentative New Date For FDA Advisory Committee Review Of Tesamorelin NDA 46
January 25, 2010: FDA To Reschedule Advisory Committee Meeting To Review Theratechnologies's Tesamorelin NDA 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 48
Contact Us 48
Disclaimer 48

List of Tables

Number of Products Under Development for HIV-Associated Lipodystrophy Syndrome, H1 2012 8
Products under Development for HIV-Associated Lipodystrophy Syndrome - Comparative Analysis, H1 2012 9
Number of Products under Development by Firms, H1 2012 10
Number of Products under Investigation by Universities/Institutes, H1 2012 12
Comparative Analysis by Late Stage Development, H1 2012 13
Comparative Analysis by Mid Clinical Stage Development, H1 2012 14
Comparative Analysis by Early Clinical Stage Development, H1 2012 15
Products under Development by Firms, H1 2012 16
Products under Investigation by Universities/Institutes, H1 2012 17
Ark Therapeutics Group plc, H1 2012 18
Zydus Cadila Healthcare Limited, H1 2012 19
Theratechnologies Inc., H1 2012 20
Assessment by Monotherapy Products, H1 2012 21
Assessment by Combination Products, H1 2012 22
Assessment by Stage and Route of Administration, H1 2012 24
Assessment by Molecule Type, H1 2012 26
HIV-Associated Lipodystrophy Syndrome Therapeutics - Drug Profile Updates 40
HIV-Associated Lipodystrophy Syndrome Therapeutics - Dormant Products 42

List of Figures

Number of Products under Development for HIV-Associated Lipodystrophy Syndrome, H1 2012 8
Products under Development for HIV-Associated Lipodystrophy Syndrome - Comparative Analysis, H1 2012 9
Products under Development by Firms, H1 2012 10
Products under Investigation by Universities/Institutes, H1 2012 11
Late Stage Products, H1 2012 13
Mid Clinical Stage Products, H1 2012 14
Early Clinical Stage Products, H1 2012 15
Assessment by Monotherapy Products, H1 2012 21
Assessment by Combination Products, H1 2012 22
Assessment by Route of Administration, H1 2012 23
Assessment by Stage and Route of Administration, H1 2012 24
Assessment by Molecule Type, H1 2012 25
Assessment by Stage and Molecule Type, H1 2012 26

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.